Business, Policy & Funding
Breaking news on diagnostics business, policy, and funding.
Harbinger Health Raises $140 Million in Series B Financing
The firm said the funds will enable completion of clinical validation of its first blood-based cancer screening product ahead of an anticipated 2025 launch.
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
The order-dependent contract is for maintenance and support of a version of the BioFire FilmArray 2.0 molecular diagnostic instrument through January 2029.
Thermo Fisher Scientific Gets FDA Clearance for Neuroendocrine Cancer Assay
The BRAHMS CgA II KRYPTOR immunoassay is for use to track tumor progression for neuroendocrine cancer patients by measuring CgA concentration in serum.
Evvy Closes $14M Series A for Vaginal Microbiome Testing, Launches Add-on STI Screen
The New York-based firm will use the funds to scale access to its testing, discover new vaginal health biomarkers, and validate outcomes of its service.
The firm's stock price has declined almost 98 percent since its initial public offering in 2021, and some investors have expressed doubts about the future direction of the company.